A detailed history of Seelaus Asset Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Seelaus Asset Management LLC holds 13,000 shares of RCUS stock, worth $198,900. This represents 0.21% of its overall portfolio holdings.

Number of Shares
13,000
Holding current value
$198,900
% of portfolio
0.21%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$14.59 - $18.48 $189,670 - $240,240
13,000 New
13,000 $197,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.1B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Seelaus Asset Management LLC Portfolio

Follow Seelaus Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seelaus Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Seelaus Asset Management LLC with notifications on news.